

Study	Lambda
China1	0.93
China2	1.00
China3	1.01
Japan	0.99
Thailand	1.00
Russia	1.00
Estonia	1.00
Germany	1.00
Gambia	1.00
Ghana	1.00
SAC_A	1.03
SAC_M	1.00

Figure S1: QQ-plot (left) from the MR-MEGA analysis of all 12 datasets with genomic control correction, including two PCs as covariates. The lambda value of 1.00 suggests no significant inflation or deflation of p-values. Lambda values for the input data (right).





Figure S2: Trans ethnic meta-analysis results for the three replicated HLA epitope association, showing consistent direction of genetic effects between the input studies.

Observed Outcome



Association

Figure S3: Proportion of variants that had a significant change in association p-value following the inclusion of the force of infection p-value for different p-value bins.



Figure S4: Forest plots for the suggestive chromosome 9 peaks, rs4576509 (left) and rs6477824 (right) for the transethnic Mr-MEGA analysis including all 12 cohorts.



Figure S5: Forest plots for the suggestive chromosome 11 peak, rs12362545, for the trans-ethnic Mr-MEGA analysis including all 12 cohorts.



Figure S6: Forest plots for the suggestive chromosome 16 peak, rs35787595, for the trans-ethnic Mr-MEGA analysis including all 12 cohorts.



Figure S7: QQ-plots for the region-specific FE meta-analysis using GCC and implemented in GWAMA

Chr 16: rs35787595



Figure S8: Manhattan plot of all p-values (>=2studies) for the European subgroup analysis. FE model with GCC implemented in GWAMA.



Figure S9: Manhattan plot of all p-values (>=2studies) for the Asian subgroup analysis. FE model with GCC implemented in GWAMA.



Figure S10: Manhattan plot of all p-values (>=2studies) for the African subgroup analysis. FE model with GCC implemented in GWAMA.

Dataset	Populati	Cases/	Control	ТВ	ТВ	Estimated	#SNPs	Genotyp	Reference
	on	Contr	definitio	diagnosis	prevale	proportio		ing	
		OIS	n		nce per	n of		platform	
					100 000 na	ever			
					pa.	exposed			
						to Mtb			
						(±SD)**			
China 1*	Asian		A peer- nominat ed approac h was	Acid-fast staining and culturing of Mth	89	0.302 (0.101)	7 710 153		<u>thye@bni-</u> <u>hamburg.de</u> (unpublishe <u>d)</u>
		483/ 587	used to recruit control subjects to the study.** *	from sputum samples.				Affymetr ix Genome -Wide Human SNP Array 6.0	
China 2*	Asian		A peer- nominat ed approac h was used to recruit control subjects	Acid-fast staining and culturing of Mtb from sputum samples.	89	0.302 (0.101)	9 769 029	Illumina Human	magdakellis @gmail.com (unpublishe d)
		1290/ 1145	to the study.** *					OmniZho nghua-8 chips.	
China 3	Asian		Controls were defined as individua ls with no history of TB, normal radiogra phic findings, and	Acid-fast staining and culturing of Mtb from sputum samples.	89	0.302 (0.101)	9 726 450	Illumina	(Qi et al., 2017)
		972/ 1537	negative purified protein de-					Human OmniZho nghua-8 chips.	

Dataset	Populati	Cases/	Control	ТВ	ТВ	Estimated	#SNPs	Genotyp	Reference
	on.	Contr	definitio	diagnosis	prevale	proportio		ing	
		ols	n	-	nce per	n of		platform	
					100 000	controls			
					pa.	ever			
						exposed			
						to <i>Mtb</i>			
						(±SD)**			
			rivative						
			(PPD)						
			skin						
			tests (<5						
Theilen	A =: =		mm)	A stal for st	226	0.404	C 700		(D. d. a. la aciatina
i nailan	Asian		BIOOD	Acid-fast	236	0.404	6 /23		(Ivianasirim
a			aonors	staining		(0.112)	358		ongkol et
			for a	anu culturing					al., 2012)
			history	of Mth					
			of TB	from					
			and a	sputum					
			family	samples.				Illumina	
		433/	history	-				Human6	
		295	of TB					10-Quad	
Japan	Asian		Blood	Acid-fast	23	0.142	9 051		(Mahasirim
			donors	staining		(0.125)	051		ongkol et
			screened	and					al., 2012)
			for a	culturing					
			history	of Mtb					
			OTIB	Trom					
			family	sputum				Illumina	
		751/	history	sampies.				HumanH	
		3199	of TB					ap550	
Russia*	Europea		Healthy	Acid-fast	109	0.191	10 878		(Curtis et al.,
	n		adult	staining		(0.093)	777		2015)
			blood	and					
			bank	culturing					
			donors	of Mtb					
			with no	from					
			history	sputum					
			ot FB.	samples.					
			IVILD infoction					٨ffumatr	
			status of					iv	
			these					Genome	
			controls					-Wide	
			was					Human	
		5914/	unknow					SNP	
		6022	n					Array 6.0	
Estonia	Europea		Healthy	Biobank	13	0.116	10 611		andres.mets
	n	62/	Biobank	TB cases		(0.093)	556	Illumina	palu@ut.ee
		2660	controls					370K	

Dataset	Populati	Cases/	Control	тв	тв	Estimated	#SNPs	Genotyp	Reference
	on	Contr	definitio	diagnosis	prevale	proportio		ing	
	•	ols	n		nce ner	n of		nlatform	
		013			100 000	controls		plationin	
					100 000	ovor			
					ha.	ever			
						exposed			
						(±SD)**			
									<u>(unpublishe</u>
									<u>d)</u>
Germa	Europea		A peer-	NA	7.8	0.067	10 602		<u>thye@bni-</u>
ny*	n		nominat			(0.081)	193		<u>hamburg.de</u>
			ed						<u>(unpublishe</u>
			approac						<u>d)</u>
			h was						_
			used to						
			recruit						
			control						
			subjects						
			to the					Illumina	
		586/	study **					Omni2 5	
		333	*					+exome	
Cambia	African	555	Anoor	ΝΑ	176	0.200	10 62/	· CAOIIIC	Consortium
sampia	Anncan		A peer-	NA	120	0.200	10 054		2007)
-			nominat			(0.089)	017		, 2007)
			eu						
			approac						
			h was						
			used to						
			recruit						
			control						
			subjects					Affymetr	
			to the					ix	
		1316/	study.**					GeneChi	
		1382	*					р 500К	
Ghana*	African	1359/	A peer-	Acid-fast	282	0.539	19 029		(Thye et al.,
		1952	nominat	staining		(0.198)	214		2010)
			ed	and					
			approac	culturing					
			h was	of Mtb					
			used to	from				Affymetr	
			recruit	sputum				ix ,	
			control	samples.				Genome	
			subiects					-Wide	
			to the					Human	
			study.**					SNP	
			*					Arrav 6.0	
SAC(A)	African		Commun	Acid-fast	717	0.436	9 227		(Dava et al
* ^	/		itv	staining	· _ ·	(0.127)	330		2014b)
			contacts	and		(,			,
			assumed	culturing					
		577/1	tobo	of M+h				Affumatr	
		9	exposed	from				ix 500k	

Dataset	Populati	Cases/	Control	ТВ	ТВ	Estimated	#SNPs	Genotyp	Reference
	on	Contr	definitio	diagnosis	prevale	proportio		ing	
		ols	n		nce per	n of		platform	
					100 000	controls			
					pa.	ever			
						exposed			
						to <i>Mtb</i>			
						(±SD)**			
			and	sputum					
			latently	samples.					
			infected						
			with						
			Mtb						
SAC(M)	African		Commun	Acid-fast	717	0.436	11 371		(Schurz et
* ^			ity	staining		(0.127)	838		al., 2019a)
			contacts	and					
			assumed	culturing					
			to be	of Mtb					
			exposed	from					
			and	sputum					
			latently	samples.					
			infected	-				Illumina	
		410/	with					MEGA	
		405	Mtb					array	

* Raw genotyping data available

** Estimated proportion of control individuals ever infected with Mtb by age 35-44 in 2010, based on data from Houben & Dodd

^ SAC(A/M): South African admixed population (SAC) Affymetrix (A) and MEGA (M) array data

*** With this approach, patient participants were asked to take an information sheet home and to invite friends/neighbours to participate in the study. It was made clear that the invitee should have no history of TB, have no symptoms of TB (e.g. cough), be of similar age, sex and ethnicity and, if they agree to participate, they should join the patient on his/her next clinical follow-up. At the clinic, it was emphasized again that the participant is under no obligation to take part. They were informed as to the nature and scope of the project and their role and rights as a participant prior to providing written consent. For all participants, age, sex, ethnicity, education, occupation, and TB vaccination data were collected in a short questionnaire.

Table S2: Polygenic heritability estimates at different TB prevalence rates.

Cohort	Prevalence	VG (SE)*		V(G)/Vp_L (SE)*	
			0.1x'	1x '	10x '
China1	0.00089	0.125 (0.045)	0.195 (0.069)	0.349 (0.124)	0.542 (0.192)
China2	0.00089	0.149 (0.037)	0.116 (0.028)	0.208 (0.050)	0.324 (0.078)
China3	0.00088	0.134 (0.037)	0.119 (0.032)	0.216 (0.059)	0.336 (0.091)
Japan	0.00023	0.027 (0.014)	0.012 (0.006)	0.083 (0.043)	0.119 (0.061)
Thailand	0.00236	0.029 (0.024)	0.036 (0.029)	0.051 (0.042)	0.087 (0.070)
Russia	0.00109	0.411 (0.014)	0.219 (0.005)	0.357 (0.008)	0.563 (0.013)
Germany	0.00008	0.231 (0.054)	0.007 (0.001)	0.189 (0.041)	0.366 (0.080)
Gambia	0.00126	0.304 (0.033)	0.235 (0.023)	0.366 (0.036)	0.583 (0.058)
Ghana	0.00282	0.091 (0.034)	0.116 (0.043)	0.168 (0.063)	0.286 (0.107)
SAC	0.00717	0.151 (0.096)	0.196 (0.123)	0.300 (0.188)	0.556 (0.348)
Average	NA	0.240 (0.009)	0.153 (0.007)	0.263 (0.013)	0.419 (0.022)

* VG (SE): Genetic variance estimate and standard error

*V(G)/Vp_L (SE): Ratio of genetic variance to phenotypic variance, estimate and standard error 'Prevalence multiplier

Table S3: Suggestive associations (p-value <= $1e^{-5}$) for the multi-ancestry analysis including data from all 12 datasetsimplementing MR-Mega analysis with GCC.

					CAD						_
Manhan	Charaman				D	F A			Samp	Datasa	P-
Ivlarker	Chromoso	D			scor	EA	NEA	EAF	ie	Datase	valu
Name	me	Position	Gene	Location	е	^	^	~	size	ts	е
rs2857899		3250564			1.76			0.03	2437		2.90
0	6	3	HLA-DRB5	intergenic	6	G	А	7	8	7	e ⁻⁰⁷
rs1148039		3269400						0.39	2437		4.88
04	6	1	HLA-DQB3	intergenic	0.78	С	Т	3	7	7	e ⁻⁰⁶
rs1117186		3269740			12.5			0.16	1820		2.72
86	6	5	HLA-DQB3	intergenic	7	С	Т	9	5	5	e ⁻⁰⁶
		3278871						0.23	2635		4.52
rs2621322	6	2	TAP2	intronic	0.27	G	Т	1	9	10	e ⁻⁰⁶
rs1460495		3255514						0.03	2437		1.03
19	6	2	HLA-DRB1	intronic	0.1	С	G	5	7	7	e ⁻⁰⁶
rs7340953		3261162		downstre	12.5			0.03	2437		1.52
8	6	4	HLA-DQA1	am	1	Т	G	5	7	7	e ⁻⁰⁶
rs2838332		3259403						0.26	2633		6.36
3	6	9	HLA-DQA1	intergenic	4.47	А	G	0	0	10	e ⁻⁰⁸
rs2868098		3260657			12.2			0.23	2558		1.01
1	6	9	HLA-DQA1	intronic	3	А	G	2	4	9	e ⁻⁰⁷
rs2860666		3261486						0.19	2555		2.84
2	6	4	HLA-DQA1	intergenic	5.72	G	C	7	0	9	e ⁻⁰⁶
rs1129842		3261788						0.18	2437		2.14
11	6	9	HLA-DQA1	intergenic	5.57	Т	G	4	8	7	e ⁻⁰⁶

					CAD D				Samp		P-
Marker Name	Chromoso me	Position	Gene	Location	scor e	EA ^	NEA ^	EAF ^	le size	Datase ts	valu e
rs2858331	6	3268127 7	XXbac- BPG254F2 3.7	intergenic	2.49	G	A	0.48 2	2635 2	10	7.02 e ⁻⁰⁷
rs6913309	6	3233984 0	C6orf10	upstream	3.55	А	т	0.27 4	2633 0	10	3.18 e ⁻⁰⁷
rs8023415 5	6	3251248 3	RNU1-61P	intergenic	2.83	с	G	0.16 9	2511 0	8	2.21 e ⁻⁰⁷
rs1157527 43	6	3255916 3	HLA-DRB1	intergenic	6.93	т	с	0.22 8	2510 2	8	2.67 e ⁻⁰⁷
rs6477824	9	1142874 53	ZNF483	UTR5	9.43	с	Т	0.74 5	3127 9	10	2.99 e ⁻⁰⁷
rs4576509	9	2329403 7	SUMO2P2	intergenic	16.2	G	с	0.76 8	3122 4	10	7.40 e ⁻⁰⁷
rs1236254 5	11	7573173	PPFIBP2	intronic	5.16 7	Т	G	0.07 8	3263 3	12	1.24 e ⁻⁰⁶
rs3578759 5	16	7546684 7	CFDP1	intronic	4.5	с	G	0.51 1	2829 9	9	5.41 e ⁻⁰⁶

Table S4: Results for the concordance in direction of effect analysis for alp-value thresholds and reference populations (for SNNP selection)

Reference	Threshold	Comparison	p-value	probability of success
	p-value <= 0.001	Europe vs. Africa	0.477	0.503
		Europe vs. Asia	0.831	0.474
	0.001< p-value <= 0.01	Europe vs. Africa	0.00614	0.531
Furone		Europe vs. Asia	0.2843	0.507
Luiope	0.01< p-value <= 0.5	Europe vs. Africa	0.220	0.505
		Europe vs. Asia	0.650	0.497
	0.5< p-value <= 1.0	Europe vs. Africa	0.286	0.504
		Europe vs. Asia	0.558	0.499
	p-value <= 0.001	Asia vs. Europe	0.293	0.518
		Asia vs. Africa	0.707	0.485
	0.001< p-value <= 0.01	Asia vs. Europe	0.698	0.493
Asia		Asia vs. Africa	0.68	0.494
	0.01< p-value <= 0.5	Asia vs. Europe	0.599	0.498
		Asia vs. Africa	0.541	0.499
	0.5< p-value <= 1.0	Asia vs. Europe	0.271	0.504
		Asia vs. Africa	0.482	0.500
	p-value <= 0.001	Africa vs. Europe	0.432	0.504
		Africa vs. Asia	0.885	0.475
	0.001< p-value <= 0.01	Africa vs. Europe	0.628	0.496
Africa		Africa vs. Asia	0.418	0.502
	0.01< p-value <= 0.5	Africa vs. Europe	0.091	0.509
		Africa vs. Asia	0.75	0.495
	0.5< p-value <= 1.0	Africa vs. Europe	0.014	0.516
		Africa vs. Asia	0.627	0.497

Table S5: Suggestive associations for the European and Asian ancestry-specific FE analysis (with GCC)

Rs number	EA	NE	EAF	Gen	OR	OR	OR	p-	Datas	Sample	Effect	Рор
(chr)	^	Α^	^	е		95L*	95U*	value	ets	size	s**	
rs28383206	G	А	0.2	HLA	0.8	0.77	0.88	7.06e	3	14791	+	Europ
(6)			0		2			-08				ean
rs3935174	Т	А	0.3	ASA	0.8	0.82	0.92	1.00e	3	14791	-+-	Europ
(8)			0	P1	7			-06				ean
rs12362545	Т	G	0.0	PFIB	1.3	1.21	1.51	1.06e	3	14791	+++	Europ
(11)			5	P2	5			-07				ean
rs14604951	С	G	0.0	HLA-	2.1	1.59	2.95	1.06e	2	3578	??+?+	Asian
9 (6)			32	DRB				-06				
				1								
rs62495207	С	G	0.4		0.8	0.77	0.904	5.10e	3	7174	;;-	Asian
(8)			6		3			-06				

* Lower (L) and upper (U) 95% confidence interval of the odds ratio (OR)

** Effect (OR) direction of individual input studies, either negative (-) positive (+) or not present (?)

^EA and EAF: Effect allele and effect allele frequency

^NEA: Non-effect allele